Clasping antibodies for high-affinity recognition of challenging antigens

Technology
In development
University
Scouted & summarized by Halo AI

NYU's Clasping Antibody Platform generates high-affinity, recombinant antibodies that use a unique cooperative binding mode to target challenging antigens, such as site-specific post-translational modifications. This technology provides highly specific, consistent, and renewable reagents for diagnostics and research, overcoming the limitations of traditional, animal-derived antibodies. NYU is seeking industry partners for commercialization.

Overview

The Clasping Antibody Platform is a synthetic technology developed by New York University researchers to produce high-performance recombinant antibodies capable of targeting challenging antigens, particularly site-specific post-translational modifications (PTMs). By utilizing a unique, binding mode-guided approach known as antigen-clasping, two antigen-binding sites work cooperatively to sandwich a single antigen. This mechanism creates an extensive binding surface, resulting in high affinity and selectivity. This platform offers a superior alternative to traditional animal-derived antibodies, providing consistent, renewable reagents for research and diagnostic applications.

Technical specifications
  • Mechanism: Employs a cooperative antigen-clasping binding mode where two distinct binding units recognize the same antigen, creating extensive interactions.
  • Performance: Achieves low nanomolar to sub-nanomolar affinity and high specificity, outperforming conventional antibodies in head-to-head comparisons like chromatin immunoprecipitation (ChIP).
  • Format: Recombinant design, including a synthetic yeast-display-based system and a novel IgG-like antibody format.
  • Consistency: Being recombinant, these antibodies exhibit minimal lot-to-lot variation and offer a stable, long-term supply.
  • Scope: Validated for various PTMs including methylation (e.g., H3K27me3, H3K9me3), phosphorylation, and others such as glycosylation and ubiquitination.
Technology readiness level

The technology is at a stage of lab validation and prototype demonstration (TRL 4-5). A suite of anti-PTM clasping antibodies has been functionally validated using techniques such as immunoprecipitation, biolayer interferometry, western blotting, and chromatin immunoprecipitation. NYU has filed a U.S. provisional patent application and is currently seeking an industry partner to support further commercialization and development.

Generated Nov 5, 2026. Please verify key information.

About New York University

New York University is a comprehensive private research university anchored in New York City, enrolling a large, diverse student body and operating a global network of campuses. Corporate engagement is enabled by co‑located engineering and computing hubs in Brooklyn and Manhattan with shared labs and facilities for prototyping and field pilots. Integration with a major hospital system supports clinical translation, IRB processes, and access to real‑world data under stringent governance. Proximity to leading industries and a mature sponsored‑research function streamline scoping, NDAs, MSAs, and talent pipelines. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DOD, and a dedicated technology transfer office manages IP, licensing, and startup creation.

Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.